Aflibercept
Aflibercept has been studied in 7 papers since 2018: 1 trial and 2 observational studies in people, 1 in animals, 2 in cells, 1 review; 2 in the past year. It is an approved medicine. The newest paper, Mar 26, 2026: “Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction”.
See all 7 papers on aflibercept
At a glance
The findings reach people, from one lab or study. 4 independent labs in 4 countries; 203 trials, none about aging, 55 with no results posted.
“aflibercept: adjusted RR 0.82; 95% CI 0.65-1.04; P = 0.10”
None of its findings points the other way.
- 4 independent labs in 4 countries
- 203 trials, none about aging, 55 with no results posted
- Funders: National Research Foundation of Korea and 4 more
- 2 of 5 findings with company ties
- 3 of 203 trials sponsored by its developers
- Human trial1
- Humans2
- Animals1
- Cells2
What did studies of aflibercept find?
5Studies of aflibercept measured 5 outcomes, among them myocardial infarction, stroke, or death, choroidal neovascularization and cellular senescence.
Myocardial infarction, stroke, or death
no changein humans1RR 0.82
1 study
Myocardial infarction, stroke, or death
no changein humans1RR 0.82
Aflibercept was not clearly linked with myocardial infarction, stroke, or death in humans (subgroup analysis by agent used for first anti-VEGF IVT) (adjusted RR 0.82; 95% CI 0.65-1.04; P = 0.10).
Humanssubgroup analysis by agent used for first anti-VEGF IVT28 days
Choroidal neovascularization
downin mice1
1 study
Choroidal neovascularization
downin mice1
Aflibercept decreases choroidal neovascularization in mice (laser-induced CNV).
Animalslaser-induced CNV
Cellular senescence
no changein human cells1
1 study
Cellular senescence
no changein human cells1
Aflibercept showed no clear effect on cellular senescence in human cells (senescent hiPSC-derived RPE cells).
Cellssenescent hiPSC-derived RPE cellsretinal pigment epithelial cellsclinical dose3 days
Cell viability
no changein human cells1
1 study
Cell viability
no changein human cells1
Aflibercept showed no clear effect on cell viability in human cells (senescent hiPSC-derived RPE cells).
Cellssenescent hiPSC-derived RPE cellsretinal pigment epithelial cellsclinical dose3 days
Beta-galactosidase
downin pig cells1
1 study
Beta-galactosidase
downin pig cells1
Aflibercept decreases beta-galactosidase in pig cells after 1 day and after 12 weeks (p<0.01 at 1 day, p<0.05 at 12 weeks).
Cellsafter 1 day and after 12 weeksretinal pigment epithelial cells125 μg/ml1 day and 12 weeks
Has aflibercept been tested in people?
0 of 203 about agingYes: 1 trial and 2 observational studies in people have been published, and 198 trials are registered.
Approved
Nov 18, 2011Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Retinopathy of Prematurity, Diabetic Macular Edema, neovascular age-related macular degeneration
Nov 21, 2012Wet Macular Degeneration, Macular Edema, Retinal Vein Occlusion, Choroidal Neovascularization, Retinopathy of Prematurity, Diabetic Macular Oedema, Macular Oedema, visual impairment, neovascular age-related macular degeneration
Feb 1, 2013Colorectal Neoplasms, Metastatic Colorectal Cancer
Aug 18, 2023Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Diabetic Macular Edema, neovascular age-related macular degeneration
Sep 15, 2023Macular Edema, Retinal Vein Occlusion, Diabetic Retinopathy, Myopia, Degenerative, Diabetic Macular Oedema, Macular Oedema, visual impairment, neovascular age-related macular degeneration
May 20, 2024Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Diabetic Macular Edema, neovascular age-related macular degeneration
All 21Fewer
Repurposing
Phase 4Recruiting2 trials
Phase 4Results posted4 trials
Phase 3Results posted9 trials
Phase 4Recruiting2 trials
Phase 3Completed2 trials
Phase 3Results posted2 trials
40 of 63Fewer
In trials
Pathologic Neovascularization
Phase 4Status unknown4 trials
Chorioretinal vascular diseases
Phase 4Results posted2 trials
Colorectal cancer metastatic
Phase 3Results posted3 trials
Center-involved diabetic macular edema
Phase 3Completed1 trial
Macular edema secondary to retinal vein occlusion
Phase 3Results posted1 trial
nAMD
Phase 3Recruiting1 trial
All 16Fewer
Readouts due
- Jan 8, 2027
- Sep 2027
Mean Visual Acuity Changes Following Five Injections of Aflibercept
Active, not recruiting
Stopped
NCT02002377TerminatedMacular degeneration
Inadequate enrollment due to investigational product becoming newly available on the Canadian market soon after study start
NCT05473715TerminatedMacular degeneration
Study terminated due to administrative reasons not related to efficacy or safety.
NCT00574275TerminatedPancreatic neoplasms
Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival
NCT00509249TerminatedLeukemia, Myelomonocytic, Chronic
Early termination for discouraging results
NCT00437034TerminatedMultiple myeloma
Poor accrual
NCT02797704TerminatedCorneal neovascularization
the treatment was found to be inefficient for all recruited patients
All 7Fewer
Who is developing aflibercept?
3 companies: Bayer, Merck Sharp & Dohme and Regeneron Pharmaceuticals.
Trial sponsors
Company19 trialsPhase 45,906 people
Company13 trialsPhase 44,688 people
Novartis Pharmaceuticals Corporation
Company2 trialsPhase 4192 people
Company18 trialsPhase 35,319 people
Company3 trialsPhase 31,198 people
Company2 trialsPhase 31,427 people
Company1 trialPhase 3413 people
Company1 trialPhase 3366 people